Core Insights - The adjustment of the national medical insurance drug catalog for 2025 has officially begun, highlighting the urgent need to establish a comprehensive drug value evaluation system [1][2] - The core functions of medical insurance involve scientifically and reasonably managing funds, which necessitates a systematic evaluation framework to assess the comprehensive value of medical products [1][2] Group 1: Importance of Real-World Data - Real-world data (RWD) is crucial for evaluating the safety, effectiveness, economic viability, fairness, accessibility, and innovation of medical products purchased by medical insurance [2][3] - The establishment of a unified medical insurance information platform has enabled the collection of extensive data, which is essential for transforming this data into actionable evidence [2][3] Group 2: Evaluation Framework - A structured real-world database should be created, along with technical guidelines to standardize and structure real-world data at the smallest granularity [3][4] - A unified evaluation system, standards, and methods should be developed to assess the comprehensive value of drugs at different stages: pre-market, pre-insurance entry, and post-insurance entry [3][4][5] Group 3: Dynamic Management of Drug Evaluation - Post-market drugs require ongoing evaluation to ensure their clinical effectiveness, utilizing real-world data for comprehensive re-evaluation [5] - New products should be compared with existing ones to determine their relative value, ensuring that only those with high comprehensive value remain in the insurance catalog [5]